Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Neal

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
Pediatric Neurology|January 24, 2012
Vigabatrin for childhood partial-onset epilepsiesHansel M Greiner, Elizabeth R Lynch, Steve Fordyce, et al.
BMJ (Clinical Research Ed.)|October 5, 2002
Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficultJenny Donovan, Nicola Mills, Monica Smith, et al.
BJU International|June 11, 2008
Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) studySimon M Collin, Chris Metcalfe, Jenny Donovan, et al.
Brain, Behavior, and Immunity|June 3, 2009
Psychological distress and prostate specific antigen levels in men with and without prostate cancerEmma L Turner, J Athene Lane, Chris Metcalfe, et al.
Cancer Epidemiology|December 27, 2017
Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case studyJose Leal, Nicky J Welton, Richard M Martin, et al.
Annals of Neurology|February 3, 2006
Rapamycin causes regression of astrocytomas in tuberous sclerosis complexDavid Neal Franz, Jennifer Leonard, Cynthia Tudor, et al.
Cancer Research|August 3, 2007
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancerLi Ma, Julie Teruya-Feldstein, Pauline Bonner, et al.
The Lancet. Digital Health|January 29, 2022
Limitations of the new ISO standard for health and wellness appsDavid Neal, Thomas Engelsma, Josephine Tan, et al.
Orphanet Journal of Rare Diseases|January 23, 2020
A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC)Johann Philipp Zöllner, David Neal Franz, Christoph Hertzberg, et al.
Journal of Health Services Research & Policy|March 21, 2009
Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services researchSian Noble, Jenny Donovan, Emma Turner, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Pediatric Neurology|January 24, 2012
Vigabatrin for childhood partial-onset epilepsiesHansel M Greiner, Elizabeth R Lynch, Steve Fordyce, et al.
BMJ (Clinical Research Ed.)|October 5, 2002
Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficultJenny Donovan, Nicola Mills, Monica Smith, et al.
BJU International|June 11, 2008
Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) studySimon M Collin, Chris Metcalfe, Jenny Donovan, et al.
Brain, Behavior, and Immunity|June 3, 2009
Psychological distress and prostate specific antigen levels in men with and without prostate cancerEmma L Turner, J Athene Lane, Chris Metcalfe, et al.
Cancer Epidemiology|December 27, 2017
Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case studyJose Leal, Nicky J Welton, Richard M Martin, et al.
Annals of Neurology|February 3, 2006
Rapamycin causes regression of astrocytomas in tuberous sclerosis complexDavid Neal Franz, Jennifer Leonard, Cynthia Tudor, et al.
Cancer Research|August 3, 2007
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancerLi Ma, Julie Teruya-Feldstein, Pauline Bonner, et al.
The Lancet. Digital Health|January 29, 2022
Limitations of the new ISO standard for health and wellness appsDavid Neal, Thomas Engelsma, Josephine Tan, et al.
Orphanet Journal of Rare Diseases|January 23, 2020
A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC)Johann Philipp Zöllner, David Neal Franz, Christoph Hertzberg, et al.
Journal of Health Services Research & Policy|March 21, 2009
Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services researchSian Noble, Jenny Donovan, Emma Turner, et al.
Pageof 13